|
|
|
|||
| Home Help Feedback Subscriptions Archive Search Table of Contents | ||||
Development, Vol 120, Issue 1 189-197, Copyright © 1994 by Company of Biologists
JOURNAL ARTICLES |
WM Baarends, MJ van Helmond, M Post, PJ van der Schoot, JW Hoogerbrugge, JP de Winter, JT Uilenbroek, B Karels, LG Wilming, JH Meijers and al. et
Department of Endocrinology and Reproduction, Faculty of Medicine and Health Sciences, Sophia Children's Hospital, Erasmus University, Rotterdam, The Netherlands.
The activin and TGF-beta type II receptors are members of a separate subfamily of transmembrane receptors with intrinsic protein kinase activity, which also includes the recently cloned TGF-beta type I receptor. We have isolated and characterized a cDNA clone (C14) encoding a new member of this subfamily. The domain structure of the C14-encoded protein corresponds with the structure of the other known transmembrane serine/threonine kinase receptors. It also contains the two inserts in the kinase domain that are characteristic for this subfamily. Using in situ hybridization, C14 mRNA was detected in the mesenchymal cells located adjacent to the mullerian ducts of males and females at day 15 (E15) of embryonic development. Marked C14 mRNA expression was also detected in the female gonads. In female E16 embryos, the C14 mRNA expression pattern remained similar to that in E15 embryos. However, in male E16 embryos C14 mRNA was detected in a circular area that includes the degenerating mullerian duct. The expression of C14 mRNA was also studied using RNase protection assays. At E15 and E16, C14 mRNA is expressed in the female as well as in the male urogenital ridge. However, at E19, a high C14 mRNA level in the female urogenital ridge contrasts with a lack of C14 mRNA in the male urogenital ridge. This correlates with the almost complete degeneration of the mullerian ducts in male embryos at E19. C14 mRNA expression was also detected in embryonic testes at E15, E16 and E19 using RNase protection assays, but at much lower levels than those found in the developing ovaries.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
![]() |
E. Shiraishi, N. Yoshinaga, T. Miura, H. Yokoi, Y. Wakamatsu, S.-I. Abe, and T. Kitano Mullerian Inhibiting Substance Is Required for Germ Cell Proliferation during Early Gonadal Differentiation in Medaka (Oryzias latipes) Endocrinology, April 1, 2008; 149(4): 1813 - 1819. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Klattig, R. Sierig, D. Kruspe, B. Besenbeck, and C. Englert Wilms' Tumor Protein Wt1 Is an Activator of the Anti-Mullerian Hormone Receptor Gene Amhr2 Mol. Cell. Biol., June 15, 2007; 27(12): 4355 - 4364. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Yin, S. Ouyang, W. Xu, X. Zhang, K. L. Fok, H. Y. Wong, J. Zhang, X. Qiu, S. Miao, H. C. Chan, et al. YWK-II protein as a novel Go-coupled receptor for Mullerian inhibiting substance in cell survival J. Cell Sci., May 1, 2007; 120(9): 1521 - 1528. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Pieretti-Vanmarcke, P. K. Donahoe, L. A. Pearsall, D. M. Dinulescu, D. C. Connolly, E. F. Halpern, M. V. Seiden, and D. T. MacLaughlin Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer PNAS, November 14, 2006; 103(46): 17426 - 17431. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. T. Tran, D. L. Segev, V. Gupta, H. Kawakubo, G. Yeo, P. K. Donahoe, and S. Maheswaran Mullerian Inhibiting Substance Regulates Androgen-Induced Gene Expression and Growth in Prostate Cancer Cells through a Nuclear Factor-{kappa}B-Dependent Smad-Independent Mechanism Mol. Endocrinol., October 1, 2006; 20(10): 2382 - 2391. [Abstract] [Full Text] [PDF] |
||||
![]() |
S J. Lin, T. F Lerch, R. W Cook, T. S Jardetzky, and T. K Woodruff The structural basis of TGF-{beta}, bone morphogenetic protein, and activin ligand binding. Reproduction, August 1, 2006; 132(2): 179 - 190. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q.-a. Yuan, H. H. Simmons, M. K. Robinson, M. Russeva, W. A. Marasco, and G. P. Adams Development of engineered antibodies specific for the Mullerian inhibiting substance type II receptor: a promising candidate for targeted therapy of ovarian cancer. Mol. Cancer Ther., August 1, 2006; 5(8): 2096 - 2105. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Mazerbourg and A. J.W. Hsueh Genomic analyses facilitate identification of receptors and signalling pathways for growth differentiation factor 9 and related orphan bone morphogenetic protein/growth differentiation factor ligands Hum. Reprod. Update, July 1, 2006; 12(4): 373 - 383. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Zhan, A. Fujino, D. T. MacLaughlin, T. F. Manganaro, P. P. Szotek, N. A. Arango, J. Teixeira, and P. K. Donahoe Mullerian inhibiting substance regulates its receptor/SMAD signaling and causes mesenchymal transition of the coelomic epithelial cells early in Mullerian duct regression Development, June 15, 2006; 133(12): 2359 - 2369. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Pieretti-Vanmarcke, P. K. Donahoe, P. Szotek, T. Manganaro, M. K. Lorenzen, J. Lorenzen, D. C. Connolly, E. F. Halpern, and D. T. MacLaughlin Recombinant Human Mullerian Inhibiting Substance Inhibits Long-term Growth of MIS Type II Receptor-Directed Transgenic Mouse Ovarian Cancers In vivo Clin. Cancer Res., March 1, 2006; 12(5): 1593 - 1598. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Mazerbourg, K. Sangkuhl, C.-W. Luo, S. Sudo, C. Klein, and A. J. W. Hsueh Identification of Receptors and Signaling Pathways for Orphan Bone Morphogenetic Protein/Growth Differentiation Factor Ligands Based on Genomic Analyses J. Biol. Chem., September 16, 2005; 280(37): 32122 - 32132. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Josso, C. Belville, N. di Clemente, and J.-Y. Picard AMH and AMH receptor defects in persistent Mullerian duct syndrome Hum. Reprod. Update, July 1, 2005; 11(4): 351 - 356. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Yin and L. Ma Development of the Mammalian Female Reproductive Tract J. Biochem., June 1, 2005; 137(6): 677 - 683. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Gupta, J. L. Carey, H. Kawakubo, A. Muzikansky, J. E. Green, P. K. Donahoe, D. T. MacLaughlin, and S. Maheswaran Mullerian inhibiting substance suppresses tumor growth in the C3(1)T antigen transgenic mouse mammary carcinoma model PNAS, March 1, 2005; 102(9): 3219 - 3224. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. J. Renaud, D. T. MacLaughlin, E. Oliva, B. R. Rueda, and P. K. Donahoe Endometrial cancer is a receptor-mediated target for Mullerian Inhibiting Substance PNAS, January 4, 2005; 102(1): 111 - 116. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Jeyasuria, Y. Ikeda, S. P. Jamin, L. Zhao, D. G. de Rooij, A. P. N. Themmen, R. R. Behringer, and K. L. Parker Cell-Specific Knockout of Steroidogenic Factor 1 Reveals Its Essential Roles in Gonadal Function Mol. Endocrinol., July 1, 2004; 18(7): 1610 - 1619. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Jorgez, M. Klysik, S. P. Jamin, R. R. Behringer, and M. M. Matzuk Granulosa Cell-Specific Inactivation of Follistatin Causes Female Fertility Defects Mol. Endocrinol., April 1, 2004; 18(4): 953 - 967. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Belville, H. Van Vlijmen, C. Ehrenfels, B. Pepinsky, A. R. Rezaie, J.-Y. Picard, N. Josso, N. d. Clemente, and R. L. Cate Mutations of the Anti-Mullerian Hormone Gene in Patients with Persistent Mullerian Duct Syndrome: Biosynthesis, Secretion, and Processing of the Abnormal Proteins and Analysis Using a Three-Dimensional Model Mol. Endocrinol., March 1, 2004; 18(3): 708 - 721. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Shimasaki, R. K. Moore, F. Otsuka, and G. F. Erickson The Bone Morphogenetic Protein System In Mammalian Reproduction Endocr. Rev., February 1, 2004; 25(1): 72 - 101. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Kobayashi, W. Shawlot, A. Kania, and R. R. Behringer Requirement of Lim1 for female reproductive tract development Development, February 1, 2004; 131(3): 539 - 549. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Pask, D. J. Whitworth, C.-A. Mao, K.-J. Wei, N. Sankovic, J. A. M. Graves, G. Shaw, M. B. Renfree, and R. R. Behringer Marsupial Anti-Mullerian Hormone Gene Structure, Regulatory Elements, and Expression Biol Reprod, January 1, 2004; 70(1): 160 - 167. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. C. Connolly, R. Bao, A. Y. Nikitin, K. C. Stephens, T. W. Poole, X. Hua, S. S. Harris, B. C. Vanderhyden, and T. C. Hamilton Female Mice Chimeric for Expression of the Simian Virus 40 TAg under Control of the MISIIR Promoter Develop Epithelial Ovarian Cancer Cancer Res., March 15, 2003; 63(6): 1389 - 1397. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. Roberts, J. A. Visser, and H. A. Ingraham Involvement of a matrix metalloproteinase in MIS-induced cell death during urogenital development Development, March 5, 2003; 129(6): 1487 - 1496. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. M. Laurich, A. M. Trbovich, F. H. O'Neill, C. P. Houk, P. M. Sluss, A. H. Payne, P. K. Donahoe, and J. Teixeira Mullerian Inhibiting Substance Blocks the Protein Kinase A-Induced Expression of Cytochrome P450 17{alpha}-Hydroxylase/C17-20 Lyase mRNA in a Mouse Leydig Cell Line Independent of cAMP Responsive Element Binding Protein Phosphorylation Endocrinology, September 1, 2002; 143(9): 3351 - 3360. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. L. L. Durlinger, M. J. G. Gruijters, P. Kramer, B. Karels, H. A. Ingraham, M. W. Nachtigal, J. Th. J. Uilenbroek, J. A. Grootegoed, and A. P. N. Themmen Anti-Mullerian Hormone Inhibits Initiation of Primordial Follicle Growth in the Mouse Ovary Endocrinology, March 1, 2002; 143(3): 1076 - 1084. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. L. L. Durlinger, M. J. G. Gruijters, P. Kramer, B. Karels, T. R. Kumar, M. M. Matzuk, U. M. Rose, F. H. de Jong, J. Th. J. Uilenbroek, J. A. Grootegoed, et al. Anti-Mullerian Hormone Attenuates the Effects of FSH on Follicle Development in the Mouse Ovary Endocrinology, November 1, 2001; 142(11): 4891 - 4899. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Teixeira, S. Maheswaran, and P. K. Donahoe Mullerian Inhibiting Substance: An Instructive Developmental Hormone with Diagnostic and Possible Therapeutic Applications Endocr. Rev., October 1, 2001; 22(5): 657 - 674. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Dutertre, L. Gouedard, F. Xavier, W.-Q. Long, N. di Clemente, J.-Y. Picard, and R. Rey Ovarian Granulosa Cell Tumors Express a Functional Membrane Receptor for Anti-Mullerian Hormone in Transgenic Mice Endocrinology, September 1, 2001; 142(9): 4040 - 4046. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. A. Hughes Minireview: Sex Differentiation Endocrinology, August 1, 2001; 142(8): 3281 - 3287. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Visser, R. Olaso, M. Verhoef-Post, P. Kramer, A. P. N. Themmen, and H. A. Ingraham The Serine/Threonine Transmembrane Receptor ALK2 Mediates Mullerian Inhibiting Substance Signaling Mol. Endocrinol., June 1, 2001; 15(6): 936 - 945. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. R. Clarke, Y. Hoshiya, S. E. Yi, X. Liu, K. M. Lyons, and P. K. Donahoe Mullerian Inhibiting Substance Signaling Uses a Bone Morphogenetic Protein (BMP)-Like Pathway Mediated by ALK2 and Induces Smad6 Expression Mol. Endocrinol., June 1, 2001; 15(6): 946 - 959. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. T. MacLaughlin, J. Teixeira, and P. K. Donahoe Perspective: Reproductive Tract Development--New Discoveries and Future Directions Endocrinology, June 1, 2001; 142(6): 2167 - 2172. [Full Text] [PDF] |
||||
![]() |
S. Nef and L. F. Parada Hormones in male sexual development Genes & Dev., December 15, 2000; 14(24): 3075 - 3086. [Full Text] |
||||
![]() |
S Allard, P Adin, L Gouedard, N di Clemente, N Josso, M. Orgebin-Crist, J. Picard, and F Xavier Molecular mechanisms of hormone-mediated Mullerian duct regression: involvement of beta-catenin Development, January 8, 2000; 127(15): 3349 - 3360. [Abstract] [PDF] |
||||
![]() |
A. L. L. Durlinger, P. Kramer, B. Karels, F. H. de Jong, J. Th. J. Uilenbroek, J. A. Grootegoed, and A. P. N. Themmen Control of Primordial Follicle Recruitment by Anti-Mullerian Hormone in the Mouse Ovary Endocrinology, December 1, 1999; 140(12): 5789 - 5796. [Abstract] [Full Text] |
||||
![]() |
J. Teixeira, D. J. Kehas, R. Antun, and P. K. Donahoe Transcriptional regulation of the rat Mullerian inhibiting substance type II receptor in rodent Leydig cells PNAS, November 23, 1999; 96(24): 13831 - 13838. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. T. Masiakos, D. T. MacLaughlin, S. Maheswaran, J. Teixeira, A. F. Fuller Jr., P. C. Shah, D. J. Kehas, M. K. Kenneally, D. M. Dombkowski, T. U. Ha, et al. Human Ovarian Cancer, Cell Lines, and Primary Ascites Cells Express the Human Mullerian Inhibiting Substance (MIS) Type II Receptor, Bind, and Are Responsive to MIS Clin. Cancer Res., November 1, 1999; 5(11): 3488 - 3499. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Teixeira, E. Fynn-Thompson, A. H. Payne, and P. K. Donahoe Mullerian-Inhibiting Substance Regulates Androgen Synthesis at the Transcriptional Level Endocrinology, October 1, 1999; 140(10): 4732 - 4738. [Abstract] [Full Text] |
||||
![]() |
M. M. Lee, C. C. Seah, P. T. Masiakos, C. M. Sottas, F. I. Preffer, P. K. Donahoe, D. T. MacLaughlin, and M. P. Hardy Mullerian-Inhibiting Substance Type II Receptor Expression and Function in Purified Rat Leydig Cells Endocrinology, June 1, 1999; 140(6): 2819 - 2827. [Abstract] [Full Text] |
||||
![]() |
Y. Mishina, D. J. Whitworth, C. Racine, and R. R. Behringer High Specificity of Mullerian-Inhibiting Substance Signaling in Vivo Endocrinology, May 1, 1999; 140(5): 2084 - 2088. [Abstract] [Full Text] |
||||
![]() |
P. d. S. Barbara, B. Moniot, F. Poulat, B. Boizet, and P. Berta Steroidogenic Factor-1 Regulates Transcription of the Human Anti-mullerian Hormone Receptor J. Biol. Chem., November 6, 1998; 273(45): 29654 - 29660. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. K. Arambepola, D. Bunick, and P. S. Cooke Thyroid Hormone and Follicle-Stimulating Hormone Regulate Mullerian-Inhibiting Substance Messenger Ribonucleic Acid Expression in Cultured Neonatal Rat Sertoli Cells Endocrinology, November 1, 1998; 139(11): 4489 - 4495. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Visser, A. McLuskey, M. Verhoef-Post, P. Kramer, J. A. Grootegoed, and A. P. N. Themmen Effect of Prenatal Exposure to Diethylstilbestrol on Mullerian Duct Development in Fetal Male Mice Endocrinology, October 1, 1998; 139(10): 4244 - 4251. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Rouiller-Fabre, S. Carmona, R. A. Merhi, R. Cate, R. Habert, and B. Vigier Effect of Anti-Mullerian Hormone on Sertoli and Leydig Cell Functions in Fetal and Immature Rats Endocrinology, March 1, 1998; 139(3): 1213 - 1220. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Racine, R. Rey, M. G. Forest, F. Louis, A. Ferre, I. Huhtaniemi, N. Josso, and N. di Clemente Receptors for anti-Mullerian hormone on Leydig cells are responsible for its effects on steroidogenesis and cell differentiation PNAS, January 20, 1998; 95(2): 594 - 599. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. HAQQ and P. K. DONAHOE Regulation of Sexual Dimorphism in Mammals Physiol Rev, January 1, 1998; 78(1): 1 - 33. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A. Catlin, V. C. Tonnu, R. G. Ebb, B. A. Pacheco, T. F. Manganaro, R. M. Ezzell, P. K. Donahoe, and J. Teixeira Mullerian Inhibiting Substance Inhibits Branching Morphogenesis and Induces Apoptosis in Fetal Rat Lung Endocrinology, February 1, 1997; 138(2): 790 - 796. [Abstract] [Full Text] [PDF] |
||||
![]() |
G Giuili, W. Shen, and H. Ingraham The nuclear receptor SF-1 mediates sexually dimorphic expression of Mullerian Inhibiting Substance, in vivo Development, January 5, 1997; 124(9): 1799 - 1807. [Abstract] [PDF] |
||||
![]() |
E. Faure, L. Gouedard, S. Imbeaud, R. Cate, J.-Y. Picard, N. Josso, and N. di Clemente Mutant Isoforms of the Anti-Mullerian Hormone Type II Receptor Are Not Expressed at the Cell Membrane J. Biol. Chem., November 29, 1996; 271(48): 30571 - 30575. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Ryden, T. Imamura, H. Jornvall, N. Belluardo, I. Neveu, M. Trupp, T. Okadome, P. ten Dijke, and C. F. Ibanez A Novel Type I Receptor Serine-Threonine Kinase Predominantly Expressed in the Adult Central Nervous System J. Biol. Chem., November 29, 1996; 271(48): 30603 - 30609. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y Mishina, R Rey, M J Finegold, M M Matzuk, N Josso, R L Cate, and R R Behringer Genetic analysis of the Mullerian-inhibiting substance signal transduction pathway in mammalian sexual differentiation. Genes & Dev., October 15, 1996; 10(20): 2577 - 2587. [Abstract] [PDF] |
||||
![]() |
D.èl. C. Eusèbe, N. di Clemente, R. Rey, C. Pieau, B. Vigier, N. Josso, and J.-Y. Picard Cloning and Expression of the Chick Anti-Müllerian Hormone Gene J. Biol. Chem., March 1, 1996; 271(9): 4798 - 4804. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Whitworth, G Shaw, and M. Renfree Gonadal sex reversal of the developing marsupial ovary in vivo and in vitro Development, January 12, 1996; 122(12): 4057 - 4063. [Abstract] [PDF] |
||||
![]() |
J Kent, S. Wheatley, J. Andrews, A. Sinclair, and P Koopman A male-specific role for SOX9 in vertebrate sex determination Development, January 9, 1996; 122(9): 2813 - 2822. [Abstract] [PDF] |
||||
![]() |
T. Nohno, T. Ishikawa, T. Saito, K. Hosokawa, S. Noji, D. H. Wolsing, and J. S. Rosenbaum Identification of a Human Type II Receptor for Bone Morphogenetic Protein-4 That Forms Differential Heteromeric Complexes with Bone Morphogenetic Protein Type I Receptors J. Biol. Chem., September 22, 1995; 270(38): 22522 - 22526. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kawabata, A. Chytil, and H. L. Moses Cloning of a Novel Type II Serine/Threonine Kinase Receptor through Interaction with the Type I Transforming Growth Factor-beta Receptor J. Biol. Chem., March 10, 1995; 270(10): 5625 - 5630. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Gouedard, Y.-G. Chen, L. Thevenet, C. Racine, S. Borie, I. Lamarre, N. Josso, J. Massague, and N. di Clemente Engagement of Bone Morphogenetic Protein Type IB Receptor and Smad1 Signaling by Anti-Mullerian Hormone and Its Type II Receptor J. Biol. Chem., September 1, 2000; 275(36): 27973 - 27978. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. L. Segev, T. U. Ha, T. T. Tran, M. Kenneally, P. Harkin, M. Jung, D. T. MacLaughlin, P. K. Donahoe, and S. Maheswaran Mullerian Inhibiting Substance Inhibits Breast Cancer Cell Growth through an NFkappa B-mediated Pathway J. Biol. Chem., September 8, 2000; 275(37): 28371 - 28379. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. U. Ha, D. L. Segev, D. Barbie, P. T. Masiakos, T. T. Tran, D. Dombkowski, M. Glander, T. R. Clarke, H. K. Lorenzo, P. K. Donahoe, et al. Mullerian Inhibiting Substance Inhibits Ovarian Cell Growth through an Rb-independent Mechanism J. Biol. Chem., November 17, 2000; 275(47): 37101 - 37109. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. L. Segev, Y. Hoshiya, A. E. Stephen, M. Hoshiya, T. T. Tran, D. T. MacLaughlin, P. K. Donahoe, and S. Maheswaran Mullerian Inhibiting Substance Regulates NFkappa B Signaling and Growth of Mammary Epithelial Cells in Vivo J. Biol. Chem., July 13, 2001; 276(29): 26799 - 26806. [Abstract] [Full Text] [PDF] |
||||
|
|